Clinical trial
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who…
NCT00058812 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00058812 |
|---|---|
| Title | Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts |
| Official title | Administration of EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts |
| Acronym | ETNA |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Epstein-Barr Virus Infections |
| Intervention type | Biological |
| Interventions | EBV specific T cells |
| Enrollment | 69 |
| Start date | May 1, 1993 |
| Primary completion | Jul 1, 2014 |
| Completion | Jul 1, 2014 |
| First posted | Apr 15, 2003 |
| Last update posted | Jan 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: